Erdafitinib (CAS: 1346242-81-6) is a quinoxaline derivative compound, acts on FGFR1/2/3/4 with mean pIC50 of ~ 9/8.5/8.5/8.25, respectively. NJ-42756493 binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.
|